Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

This study is testing a new type of CAR-T cell therapy called Meta10-BCMA — a treatment where a patient's own immune cells are genetically re-engineered in the lab to attack plasma cell cancers — in people with multiple myeloma or related plasma cell cancers that have stopped responding to multiple prior treatments. **You may be eligible if...** - You are between 19 and 75 years old - You have been diagnosed with relapsed or refractory multiple myeloma, plasma cell leukemia, or AL amyloidosis - You have already received at least 3 prior lines of treatment, including drugs from proteasome inhibitor and immunomodulatory agent classes - Your cancer cells test positive for a protein called BCMA **You may NOT be eligible if...** - You have serious active infections - You have severe heart, lung, liver, or kidney dysfunction - You have cancer that has spread to the brain - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.